Brisbane-based clinical stage biopharmaceutical company De Motu Cordis (DMC) continues to advance its lead program, bringing the world’s first inhaled epinephrine dry powder inhaler closer to market for the emergency treatment of anaphylaxis.
Over the past year the company has expanded its strategic partnership with global CDMO Catalent, securing end-to-end manufacturing and device assembly capability across its U.S. facilities. This collaboration ensures that DMC’s flagship product, DMC-IH1, is supported by world-class development, scale-up, and production expertise. The move provides a critical foundation for commercial readiness and reliable global supply chains.
In parallel, DMC has significantly strengthened its intellectual property position. The company now holds 29 granted patents across six families, with protection spanning the United States, Europe, Asia, and Australia. These patents cover both the inhaler device and its unique formulation technology, securing DMC’s competitive position in emergency medicine and supporting potential future applications beyond anaphylaxis.
For patients, DMC’s technology represents a major step forward. Traditional auto-injectors remain underused in emergencies due to hesitation, needle anxiety, or complexity of use. By delivering epinephrine through a compact, easy-to-use dry powder inhaler, DMC’s solution has the potential to reduce delays, improve outcomes, and ultimately save lives. The company’s research indicates that patients and carers are far more likely to administer an inhaled device promptly compared to an injection, particularly in stressful, time-critical scenarios.
Beyond product development, DMC is also focused on building broader pharmaceutical capability in Queensland. The company’s leadership has outlined a vision to create a lasting innovation and manufacturing footprint in the state, supporting local employment, advanced skills, and export opportunities while delivering life-saving therapies globally.
wattelstone continues to follow DMC’s progress as an example of disciplined execution and intellectual property strategy driving meaningful innovation, underscoring the role of Australian biotech in addressing global health needs.
About De Motu Cordis
De Motu Cordis is a clinical stage biopharmaceutical company based in Brisbane, Australia. The company is pioneering inhaled drug-device combinations for life-threatening allergic reactions, with a mission to make emergency treatment faster, simpler, and more accessible.
Its lead product, DMC-IH1, is the world’s first dry powder inhaler delivering epinephrine for the treatment of anaphylaxis. Designed to be needle-free, compact, and easy to use, the inhaler aims to overcome common barriers to timely intervention, ensuring that more patients receive life-saving treatment when it matters most.
DMC’s technology is backed by a global portfolio of granted patents and supported by strategic partnerships with leading development and manufacturing organisations. The company’s broader vision is to establish Queensland as a hub for advanced pharmaceutical innovation, creating therapies with worldwide reach while building enduring local capability.
